At present, clinical wound treatment primarily relies on growth factor drugs such as VEGF and erythropoietin, which have high production, storage, and transportation costs and may exhibit tumor promoting effects with continuous use, and thus fail to achieve ideal therapeutic effects (Hamed et al., 2010; Julier et al., 2017; Cao et al., 2018). The gene discussed is EPO; the disease is neoplasm.